Redeye updates on EG7 post its Q3-results which came in stronger than expected while it also saw a solid start to Q4 as well as a positive outlook for the rest of the year. We increase our estimates on the back of the strong performance and slightly lift our valuation range where the increased estimates are counter-acted by increased assumptions for the risk-free rate.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/